Sanolium AB interim report, January - March 2021

Revenue amounted to 206.7(177.9) MSEK in the first quarter, representing a growth of 16.2%.  Adjusted EBITDA amounted to 52.3(49.6)MSEK, representing a growth of 5.4%.  Revenue recognition is negatively affected by the Covid-19 situation.

Revenue in the first quarter amounted to 206.7 (177.9) MSEK, representing a growth of 16.2%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project.

Adjusted EBITDA in the first quarter amounted to 52.3 (49.6) MSEK resulting in an adjusted EBITDA margin of 25.3 (27.9)%.

Employee related expenses amounted to 127.6 (104.5) MSEK, corresponding to an increase of 22.1%. The number of full-time employees rose to 766 in the first quarter, an increase of 12,6 % from the comparable figure last year. Of these 391 were employed in Sweden and 326 were women.

Depreciation and amortization amounted to 37.5 MSEK, of which 27.3 MSEK relates to amortization of intangible assets linked to M&A activities, 4.9 MSEK refers to financial leases and 3.1 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 2.2 MSEK.

Non-recurring items amounted to 1.6 MSEK, consisting of 1.1 MSEK relating to the introduction of a new ERP system and 0.5 MSEK relate to other.

CEO comment´s

 Despite a continued pandemic situation, Cambio continued in the first quarter to deliver on its strategy in the first quarter with healthy growth and profitability.The continued Covid-19 situation and resulting pressure on the healthcare system means direct interactions with our customers remain at a low level. However,we continue to make progress and are focused on improving Cambio’s operational efficiency and productivity.MittVaccin is now an established part of the vaccination solutions market in Sweden with more than one fifth of all Covid-vaccinations carried out via the MittVaccin’s solution.

April 19th the board of directors announced me Lars Andåker as interim CEO of the company. With my extensive experience within this sector and as a member of the board I will continue to execute on the strategy of the company. I also would like to thank Peter Gille for his contribution to this company over the years.

Please find the report here. For more information from Cambio, please visit cambiogroup.com.

This information is information that Sanolium AB(publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10 am CEST on 19 February 2021. 

For further information, please contact: 

Fredrik Rüden, CFO +46 8 691 49 00 fredrik.ruden@cambio.se 

Jenny Styren, CMCO +46 8 691 49 00 jenny.styren@cambio.se

Sanolium AB, parent of the Cambio Group (“Cambio” or “the Company”) operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.